CHALLENGES IN MILD
TRAUMATIC BRAIN INJURY (MTBI) ASSESSMENT AND THE NEXT
FRONTIER IN BIOMARKER TESTING
Live event: November 11, 2021
An estimated 69 million patients1 worldwide
sustain a traumatic brain injury (TBI) each year of which
more than 80% are classified as mild (GCS 13 to 15)2.
Due to the limitations of current evaluation tools, mTBI
assessment can be time- and resource-consuming.
Join leading experts in an
upcoming webinar to learn about the latest research into
blood plasma-based biomarkers and their potential to predict
the absence of intracranial injury. During this webinar,
you’ll hear how two proteins, Ubiquitin C-terminal
hydrolase-L1 (UCH-L1) and Glial fibrillary acidic protein
(GFAP), have emerged as promising biomarkers that can be
used in conjunction with other clinical information to aid
in the evaluation of suspected mTBI patients in the ED.
1Dewan MC et al. J
Neurosurg. 2004;43(suppl):113-125.
2Korley FK et al. J
Head Trauma Rehabil. 2016;31(6):379-387.
Learning Objectives:
•
Examine challenges and shortcomings of the current
approaches to mTBI evaluation in the ED
•
Review the latest advancements in TBI biomarkers,
including identifying brain-specific biomarkers with
characteristics that offer diagnostic value in the ED
•
Describe how blood plasma-based biomarker testing can
be used in conjunction with other clinical information to
aid in the evaluation of suspected mTBI patients and reduce
diagnostic uncertainty by providing the quantitative
measurement of biomarkers producing an objective
interpretation.
•
Examine the potential for biomarker testing to reduce
unnecessary head CT, improve patient care and satisfaction,
and improve operational efficiency
|
|

PROFESSOR PETER
BIBERTHALER, MD
Professor Peter
Biberthaler’s research activities concentrate on his core
clinical focus areas. A very important aspect of these focus
areas is the care of severe and multiple trauma patients, a
major part of which is the treatment of traumatic brain
injuries.
Professor Biberthaler’s other major focus area, shoulder
surgery, is the logical consequence of his scientific
research and clinical practice in the field of traumatology.
He is the first person to have been able to visualize the
blood circulation in direct proximity to ruptures by means
of intraoperative intravital-microscopic imaging. |
|
PAUL JARVIS, MD, BSC(HONS)
MBCHB MRCP FRCEM DIP MED ED MSC
Dr. Jarvis is the
Director of Global Medical Affairs at Abbott Point of Care.
In addition, he is a practicing Emergency Medicine Physician
working in the North of England. He has over 20 years of
clinical experience with particular interests in
Neurological Emergencies and Trauma management. He has a
Masters Degree in Quality Improvement from Ashridge Business
School, United Kingdom. Parallel to his clinical work, Paul
ran a global management consultancy for 5 years, helping
hospitals around the world improve their patient flow. |
USING BIOMARKERS FOR
OBJECTIVE ASSESSMENT OF MILD TRAUMATIC BRAIN INJURY
Live event: July 22, 2021
Traumatic brain injury (TBI) is evaluated during ~5 million
ED visits annually1 of which more than 80% are
classified as mild (GCS 13 to 15)2. Due to the
limitations of current evaluation tools, mTBI assessment can
be time- and resource-consuming.
Join leading experts in an upcoming webinar to learn about
the latest research into blood-based biomarkers and their
potential to predict the absence of intracranial injury.
During this webinar, you’ll hear how two proteins, Ubiquitin
C-terminal hydrolase-L1 (UCH-L1) and Glial fibrillary acidic
protein (GFAP), have emerged as promising biomarkers that
can be used in conjunction with other clinical information
to aid in the evaluation of suspected mTBI patients in the
ED.
1Korley FK et al. J Head Trauma Rehabil.
2016;31(6):379-387.
2Dewan MC et al. J Neurosurg.
2004;43(suppl):113-125.
Learning Objectives:
•
Examine challenges and shortcomings of the current
approaches to mTBI evaluation in the ED
•
Review the latest advancements in
TBI biomarkers, including identifying brain-specific
biomarkers with characteristics that offer diagnostic value
in the ED
•
Describe how blood-based biomarker
testing can be used in conjunction with other clinical
information to aid in the evaluation of suspected mTBI
patients and reduce diagnostic uncertainty by providing a
quantifiable objective assessment
•
Examine the potential for
biomarker testing to reduce unnecessary head CT, improve
patient care and satisfaction, and improve operational
efficiency
|
 |
JESSE M. PINES, MD, MBA, MSCE
Jesse Pines MD, is the National
Director of Clinical Innovation at US Acute Care Solutions
and a Professor of Emergency Medicine at Drexel University.
Dr. Pines leads USACS’s efforts in telemedicine, alternative
payment models, and opioids. Dr. Pines is a nationally known
expert in ED quality of care, innovation, and health
services research, and has published more than 330
peer-reviewed publications and six books. Before joining
USACS in 2018, he served as the Director of the Center for
Healthcare Innovation and Policy Research and Professor at
George Washington University and Professor, and also
previously was Assistant Professor at the University of
Pennsylvania.

PAUL JARVIS, MD,
BSC(HONS) MBCHB MRCP FRCEM DIP MED ED MSC
Dr. Paul Jarvis is
the Director of Global Medical Affairs at Abbott Point of
Care. In addition, he is a practicing Emergency Medicine
Physician working in the North of England. He has over 20
years of clinical experience with particular interests in
Neurological Emergencies and Trauma management. He has a
Masters Degree in Quality Improvement from Ashridge Business
School, United Kingdom. Parallel to his clinical work, Paul
ran a global management consultancy for 5 years, helping
hospitals around the world improve their patient flow.
|
 |

JEFFREY BAZARIAN, MD
Dr. Jeffrey Bazarian is a
Professor of Emergency Medicine and Neurology with an
active, interdisciplinary, clinical research program in mild
TBI and sport concussions at the University of Rochester. He
has served as the lead investigator on projects to determine
the epidemiology and outcome of mild TBI (K23 from NINDS),
to image with DTI axonal injury acutely after mild TBI (R01
from NICHD), to determine the role of serum S100B in the
diagnosis of intracranial hemorrhage after mild TBI (New
York State Department of Health), to validate new putative
markers of axonal injury (K24 NICHD), and to investigate the
nature of white matter damage after multiple sub-concussive
head blows (NFL-Charities). His lab’s translational research
platform involving contact athletes at the University of
Rochester and Rochester Institute of Technology incorporates
DTI, fMRI, and cognitive/balance performance with head
accelerometer data, as well as with serum and whole blood
sampling for protein and genetic analysis, respectively.
|